globalbloodtx.com
Hereditary Angioedema | Global Blood Therapeutics
http://www.globalbloodtx.com/content/patients/hae.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. Hereditary angioedema (HAE) is a rare genetic disorder characterized by severe and potentially life-threatening systemic inflammation and is estimated to affect approximately 6,500 people in the United States and approximately one in 50,000 people globally. All currently marketed therapeutics for HAE must be administered intravenously or by subcutaneous injection. As a result, we believe that the availability of a safe and effective oral kalli...
globalbloodtx.com
Hereditary Angioedema | Global Blood Therapeutics
http://www.globalbloodtx.com/content/pipeline/hereditary-angioedema.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. We are currently conducting preclinical research to identify and develop an oral therapy for hereditary angioedema (HAE), a debilitating disease with limited current treatment options. HAE is a rare, genetic disorder characterized by severe and potentially life-threatening systemic inflammation. Global Blood Therapeutics Inc. Home.
globalbloodtx.com
About Global Blood Therapeutics
http://www.globalbloodtx.com/content/about/index.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. We are currently investigating GBT440 in an ongoing Phase 1/2 clinical trials in both healthy subjects and SCD patients. Additionally, we plan to develop GBT440 as a potential therapy for acute and chronic hypoxemic lung disorders, including idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS). We are also working to advance an oral kallikrein inhibitor for the prevention of hereditary angioedema (HAE) attacks.
globalbloodtx.com
GBT440 Development Strategy | Global Blood Therapeutics
http://www.globalbloodtx.com/content/gbt440/strategy.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. Based on compelling preclinical results, we initiated a Phase I/II trial of GBT440 in SCD in healthy subjects and patients with SCD in December 2014. Access information on this study on ClinicalTrials.gov. Our Approach to SCD. Global Blood Therapeutics Inc. Home.
globalbloodtx.com
GBT440 Supportive Data | Global Blood Therapeutics
http://www.globalbloodtx.com/content/gbt440/data.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. GBT440 is being investigated as an oral, once daily, direct-acting hemoglobin modifier for the chronic, prophylactic treatment of patients with sickle cell disease (SCD). In January 2015, we initiated a Phase I/II trial of GBT440 in SCD and expect early proof of concept data to be available in the second half of 2015. Key preclinical research findings show that GBT440:. Maintains oxygenated hemoglobin even under hypoxic conditions.
globalbloodtx.com
Patient Resources | Global Blood Therapeutics
http://www.globalbloodtx.com/content/patients/resources.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. In an effort to provide patients and their families with access to the latest and most valuable resources related to chronic diseases of the blood, we have compiled the following list of links. These links will take you away from the company’s website, but connect you to other trusted providers of information that we think may be useful to patients and their families. Sickle Cell Disease Association of America (SCDAA). Sickle Cell Society (UK).
globalbloodtx.com
Global Blood Therapeutics
http://www.globalbloodtx.com/index.php
Transforming Treatment of Severe Blood Disorders. Learn more ». A Commitment to Serving Patients and Their Families. Learn more ». Our Approach to SCD. About Hypoxemic Pulmonary Disorders. Global Blood Therapeutics (GBT) is dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders. GBT440 is an oral, once-daily therapy in development for patients with sickle cell disease (SCD). More news ».
globalbloodtx.com
GBT440 | Global Blood Therapeutics
http://www.globalbloodtx.com/content/gbt440/index.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. GBT440, our lead drug candidate, is being developed as an oral, once-daily therapy for patients with sickle cell disease (SCD). We believe GBT440 holds significant potential for SCD patients and are investigating the compound as a mechanism-based and potentially disease-modifying therapeutic for this grievous disease. Currently, GBT440 is being investigated in an ongoing Phase 1/2 clinical trial in both healthy subjects and SCD patients.
globalbloodtx.com
Our Approach | Global Blood Therapeutics
http://www.globalbloodtx.com/content/science/platform.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. GBT is committed to transforming the treatment of severe blood-based disorders. Our scientific focus and mission is to develop novel medicines that treat grievous blood-based disorders by arresting the underlying chemical and biological mechanisms of the disease. Our efforts have produced a pipeline of novel, mechanism-based small molecule therapeutics that we believe have the potential to address the underlying chemical and biological mechanisms ...
globalbloodtx.com
Values | Global Blood Therapeutics
http://www.globalbloodtx.com/content/about/values.php
Our Approach to SCD. About Hypoxemic Pulmonary Disorders. To revolutionize the treatment of grievous blood-based conditions. Science dedicated to patients. Embrace open communication and debate. Trust, respect, and accountability. One team, one purpose. Always do the right thing. Global Blood Therapeutics Inc. Home.
